-
How mRNA Lipids Shape Antitumor Immunity
2026-10-14
This review asks how ionizable lipids in mRNA lipid nanoparticles influence immune and tumor-research outcomes. Compared with conventional four-component LNPs, systems containing permanently anionic lipids increased splenic mRNA accumulation; in a separate preclinical study, a stearic-acid/TLR4-agonist formulation carrying OVA mRNA elicited robust immune responses and suppressed tumor growth. Compared with linear analogs, cyclic A18 headgroups activated dendritic cells and produced STING-associated antitumor immunity even in empty LNPs. These heterogeneous findings show why delivery, immune activation, antigen-specific function, and tolerability must be evaluated separately.
-
What Cas9 mRNA Adds to Vascular CRISPR Evidence
2026-10-12
Ahad et al.’s PRISMA systematic review is relevant to mRNA immunology as background, not as a cancer or mRNA-therapeutic study. Its cited murine macrophage example reports lipid-nanoparticle-delivered Cas9 mRNA used for Nlrp3 editing, with lower IL-1β and IL-18 secretion and improved septic-shock survival and glucose tolerance; the review passage does not identify the comparator, time points, or effect sizes, so these findings should not be treated as quantified advantages. The review’s 17-study evidence base—8 in vitro, 6 animal, and 3 human studies—is heterogeneous and mainly vascular, limiting direct transfer to tumor research or to cytokine-, antigen-, or co-stimulatory-ligand-encoding mRNA.
-
dsRNA Control in Cancer mRNA Studies
2026-10-09
Liu et al.’s review describes one cited primary-cell transfection study in which octadecyl-based chromatographic purification was associated with a 10- to 1000-fold increase in target-protein expression and reduced induction of interferon and inflammatory factors. It also reports that dsRNA-depleted CAR-encoding mRNA, compared with untreated preparations, was associated with greater CAR expression and T-cell functionality; these findings provide methods background rather than direct evidence of cancer efficacy or product validation.
-
mRNA Editing in Pediatric Immune Research
2026-10-07
Compared with delivery approaches that sustain editor expression, the review presents mRNA as transient and non-integrating, with potential advantages for exposure control and repeat administration. Compared with some viral platforms, however, LNP-based mRNA delivery remains limited by rapid clearance, tissue specificity, and blood–brain-barrier access. The review reports no new mRNA immune-cell experiment, tumor outcome, or direct functional comparison, so its conclusions are background rather than product or platform validation.
-
mRNA Strategies for Tumor Immunity and Cell Engineering
2026-10-05
This review asks how administered or engineered mRNA can generate antitumor immunity, localize cytokine activity, and transiently reprogram immune cells. In the summarized phase 2b melanoma comparison, mRNA-4157 plus pembrolizumab was associated with higher 18-month recurrence-free survival than pembrolizumab alone, 79% versus 62%, while distant metastasis-free survival was 92% versus 77%. In a lung-cancer model, IL-12 mRNA delivered by extracellular vesicles was reported to produce greater lung accumulation and fewer off-target effects than IL-12 mRNA delivered by liposomes.
-
What Spleen-Targeted mRNA Actually Demonstrates
2026-10-02
In mice, spleen-targeted polymer–lipid hybrid nanoparticles (PLHNPs) delivered Cre mRNA to several splenic and lymph-node immune populations and supported functional immune readouts with ovalbumin mRNA. At 1–2.5% spleen-targeting polymer, luciferase mRNA expression was comparable to or higher than that from lipid-only Spleen-SORT LNPs containing 10% 18PA, whereas 5–10% polymer reduced spleen expression. After prime–boost ovalbumin mRNA immunization, splenic dendritic cells upregulated CD80 and CD86, OVA-specific CD8+ T cells expanded, and OVA-specific IgG remained high for one month. These findings support a research platform for studying antigen-encoding mRNA and immune-cell delivery, not demonstrated antitumor efficacy or treatment use.
-
Choosing Influenza mRNA Designs for Broad Immunity
2026-09-30
This review asks how antigen choice, RNA architecture, and administration route shape breadth and tolerability in influenza mRNA research. Compared with licensed Afluria quadrivalent vaccine, phase 1/2 mRNA-1010 produced higher antibody responses against certain mismatched H3N2 variants; compared with linear mRNA, self-amplifying RNA is described as supporting prolonged expression at lower initial doses but tending toward more T-cell-dominant responses. Compared with conventional IIVs and LAIVs, mRNA vaccines were associated with more frequent or pronounced local and systemic reactions, so broad immune endpoints must be interpreted alongside expression duration, route-specific barriers, and tolerability.
-
Transient CAR mRNA Engineering in Cardiac Fibrosis Research
2026-09-28
This cardiovascular review offers background for studying transient mRNA-based immune-cell engineering. It summarizes preclinical CAR-T and CAR-macrophage approaches to cardiac fibrosis, alongside separate IL-10 mRNA studies in atherosclerosis. These are findings from studies cited by the review—not new experiments in the review—and do not establish efficacy in cancer models or clinical treatment.
-
Source Excluded Under Reuse Restrictions
2026-09-25
This paper is not summarized because the supplied source states that all rights are reserved, including for text and data mining.
-
PTEN mRNA–HA-LNP Transdermal Melanoma Study
2026-09-23
Kim et al. evaluated hyaluronate-conjugated lipid nanoparticles for topical delivery of full-length PTEN mRNA in melanoma models. The formulation restored PTEN expression, reduced B16F10 melanoma-cell viability, increased markers consistent with immunogenic cell death, and suppressed tumor growth after repeated topical dosing in mice. The findings support a research platform for localized mRNA delivery, while the small, short-term preclinical study does not establish metastatic control, immune memory, comprehensive toxicity, or clinical efficacy.
-
EVMP mRNA Delivery for Lung Tumor Immunology
2026-09-22
Yu and colleagues developed a self-assembling enveloped virus-mimicking particle for extrahepatic mRNA delivery. In mouse lung metastasis models, the optimized carrier delivered Cre or luciferase mRNA to lung cell populations and enabled IL-12 mRNA expression associated with reduced tumor burden, altered tumor immune populations, and longer survival. The findings remain preclinical, and the mechanism of organ selectivity and the durability of tolerability require further study.
-
CD80/4-1BBL mRNA-Engineered T-Cell Vaccines
2026-09-21
Cho et al. evaluated expanded CD4 T cells transiently engineered with mRNAs encoding CD80, 4-1BBL, or both. The dual-ligand cells showed increased vitality, stronger CD8 T-cell proliferation and cytotoxicity, tumor cures in the established EG7 model, memory responses, and therapeutic antitumor activity against B16 melanoma. The report is a preclinical poster study and does not establish clinical efficacy or formal tolerability.
-
CARVac mRNA and CLDN6 CAR T Cells
2026-09-18
This introduction examines a first-in-human phase 1/2 study of CLDN6-targeted CAR T cells combined with serial nanoparticulate CLDN6 mRNA vaccination, emphasizing the vaccine’s proposed immune-amplifying role, reported safety and response signals, and unresolved dose-finding limitations.
-
mRNA-Loaded Dendritic Cells in Melanoma
2026-09-16
This single-center pilot study evaluated long-term outcomes, tolerability, and immune responses after administering autologous dendritic cells engineered ex vivo with melanoma-antigen mRNAs to patients rendered disease-free by metastasis resection. The findings are encouraging but cannot establish the independent effect of the mRNA-engineered cells because interferon alfa-2b, heterogeneous treatment cohorts, salvage therapy, and selection factors were also involved.
-
Cholesterol in mRNA-LNP Workflows
2026-08-27
Cholesterol is a controllable membrane variable for mRNA-LNP formulation, fluidity testing, and localized delivery studies. This practical guide connects solvent handling and assay design with the intravesical p21 mRNA-LNP strategy while distinguishing published findings from optimization recommendations.